Friday, May 24, 2019

Earth Science Tech Inc. (ETST) Exploring Exciting Opportunities in 2019


  • The company’s strategic partnerships expand its product placement, while its white-labeling program captures additional market share
  • ETST is committed to improving women’s health worldwide with the launch of Hygee
  • The company continues to explore expansion of product placement, both online and in retail spaces
Florida-based biotech company Earth Science Tech Inc. (OTCQB: ETST) operates in the fields of hemp cannabinoid, nutraceutical, pharmaceutical and medical device research and development. The company’s focus on strategic partnerships and becoming a global leader in the CBD sector, along with its commitment to bringing cutting-edge pharmaceutical and medical-device offerings to market, has put ETST in an intriguing position.

Strategic partnerships are key to ETST’s success. In February 2019, the company announced (http://ibn.fm/jHVNM) its entry into agreements with CannaBiz and Dessert Sun Distribution to provide high-grade, full-spectrum products to pharmacies, chiropractors, dispensaries, athletic clubs and clinics throughout the United States. The company has also created a way for other marketers to rebrand ETST’s full-spectrum cannabinoids line following countless white-labeling inquiries. By fulfilling these inquiries, the company is able to capture even more market share.

ETST is committed to bringing cutting-edge pharmaceutical and medical devices to market. Earth Science Pharmaceutical Inc., a wholly owned subsidiary of ETST, is focused on offering low-cost diagnostic tools, testing processes, medical devices and vaccines for women to detect and treat sexually transmitted illnesses.

The company’s first medical device to market is Hygee. Designed to detect STIs including chlamydia, Hygee is now ready for export, the company reports. Queen Concept Inc. has entered into a distribution agreement with ETST, making it the exclusive distributor of Hygee in Vietnam for the next five years. Nearly 7.5 million women in Vietnam fall within the demographic recommended for testing. Vietnam is the first of many countries that ETST is targeting.

Chlamydia is a global issue, with an estimated 130 million new cases diagnosed yearly. Diagnosing and treating chlamydia is particularly important for pregnant women, as the disease can be passed to the baby during childbirth. Following the launch of Hygee in Vietnam, marketing efforts will target North America, South America, Asia and Africa. Hygee packaging will feature English, French, Portuguese, Spanish, Vietnamese and Arabic in an effort to reach the 1.5 billion people who claim one of those languages as their mother tongue (http://ibn.fm/h2aEs). ETST is dedicated to revolutionizing women’s health worldwide.

Operating through four wholly owned subsidiaries, the company continues to explore expansion of product placement, both online and in retail spaces, as it develops a world leader role in the CBD space.

“I’m excited to share that our sales during the past three quarters have consistently increased over 100% every month,” ETST Chairman Nickolas S. Tabraue stated in a news release (http://ibn.fm/0T0Ya). “We have also received countless white-labeling inquires, and thanks to our reliable source and manufacturer, we are now able to fulfill these inquires and capture even more market share. We have a lot of opportunity on deck for 2019.”

For more information, visit the company’s website at www.EarthScienceTech.com

NOTE TO INVESTORS: The latest news and updates relating to ETST are available in the company’s newsroom at http://ibn.fm/ETST

About MissionIR

MissionIR is primarily focused on strategic communications. We have executed countless communications programs to address the needs of companies ranging from start-ups to established industry leaders, gaining valuable experience and the expertise necessary to determine the most effective strategy for any given situation.

For more information, visit www.MissionIR.com

MissionIR (MIR)
Atlanta, Georgia
www.MissionIR.com
404.941.8975 Office
Editor@MissionIR.com

Please see full terms of use and disclaimers on the Mission Investor Relations website applicable to all content provided by MIR, wherever published or re-published: http://www.missionir.com/disclaimer.html